[{"question": "How long should a trial period of LTRA be given to children under 5 with suspected uncontrolled asthma?", "generated_answer": "The context does not provide information on the trial period for LTRA (Leukotriene Receptor Antagonist) in children under 5 with suspected uncontrolled asthma. The context only discusses the diagnostic process for asthma in children under 5, and the recommended empirical treatment with a low dose of inhaled corticosteroid (ICS) for a period of 8 to 12 weeks.", "true_answer": "8 to 12 weeks.", "relevant_docs": ["conditions#notice-of -right s).Page 35 of\n64 These can be quantified b y questionnair es such as t he Ast hma Contr ol Questionnair e or \nAsthma Contr ol test. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 36 of\n64 Recommenda tions f or research \nThe guideline committ ee has made t he following r ecommendations f or resear ch. \nKey recommenda tions f or research \n1 Medicines f or ini tial manag emen t \nWhat is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid \n(ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\nneeded' strat egies (f or example ICS/f ormot erol) as t he initial standar d treatment f or \nasthma in childr en aged 5 t o 11 y ears? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on medicines f or initial management in \nchildr en aged 5 t o 11. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management . \n2 Medicine c ombina tion and se quencing \nWhat is t he best st ep-up tr eatment f or people whose ast hma is not contr olled on a \ncombination inhaler of ICS plus f ormot erol used as needed? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on medicine combination and \nsequencing in people aged 12 and o ver. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \ndrug combinations and sequencing f or ast hma management . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)", "asthma. \nThe committ ee w ere awar e that t here can be dela ys in obtaining spir ometr y, FeNO \nmeasur ement s or skin prick t esting, and t hat it ma y not be possible t o get blood samples \nfrom some childr en. It is hoped t hat access t o these t ests will impr ove. But if t he tests are \nnot a vailable or t here is a significant dela y in obtaining t hem, t he committ ee agr eed it \nwould be r easonable t o use PEF v ariability as a substitut e rule-in t est. \nThe best single t est is a br onchial challenge t est, but t hese ar e also not r eadily a vailable \nand cannot be done in primar y car e. If t here is still diagnostic doubt aft er per forming ot her \ntests, the committ ee agr eed t hat a r eferral t o an ast hma specialist should be made f or a \nsecond opinion, including consideration of a challenge t est. \nFurther r esear ch \nAlthough t here is e vidence underpinning each of t he tests included in t he recommended \ndiagnostic sequences f or adult s and f or childr en aged 5 t o 16 y ears, t he committ ee \nackno wledged t hat t he sequences t hemselv es ha ve not been t ested. The clinical and \ncost-effectiv eness of t he recommended diagnostic pr ocess should be f ormally e valuat ed. \nChildr en under 5 \nThe main issue in t his age gr oup is diff erentiating ast hma fr om sympt oms caused b y \nrecurr ent viral inf ections. The committ ee w ere awar e of e vidence out side t he review of \ndiagnostic t ests sho wing t hat ast hma is mor e likely than r ecurr ent viral wheez e when t he \nepisodes ar e frequent or se vere, when t hey occur in t he absence of ot her signs of viral \nillness and when t he child sho ws ot her e vidence of at opy. On t his basis, t hey agr eed t hat \nyoung childr en wit h recurr ent wheez e and f eatur es suggesting ast hma should be tr eated \nempirically wit h a lo w dose of inhaled cor ticost eroid (ICS) f or a period of 8 t o 12 w eeks. If"], "eval_score_GPT4": "2", "eval_feedback_GPT4": "The response provided does not directly answer the question regarding the trial period for LTRA in children under 5 with suspected uncontrolled asthma. Instead, it discusses the diagnostic process and the use of inhaled corticosteroids (ICS) for a different duration. While the response is related to asthma treatment in children, it does not address the specific question about the duration of LTRA treatment. Therefore, the response is mostly incorrect as it provides information about a different treatment and timeframe."}, {"question": "What organization provides guidelines for hypertension diagnosis and management in adults?", "generated_answer": "The National Institute for Health and Care Excellence (NICE) provides guidelines for hypertension diagnosis and management in adults.", "true_answer": "NICE (National Institute for Health and Care Excellence).", "relevant_docs": ["cardiovascular disease . \nFull details of t he evidence and t he committ ee's discussion ar e in t he evidence r eview \nJ: blood pr essur e tar gets. Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 30 of\n52 Rationale and im pact \nThese sections briefly e xplain wh y the committ ee made t he recommendations and ho w \nthey might aff ect practice. The y link t o details of t he evidence and a full description of t he \ncommitt ee's discussion. \nDiagnosing h yper tension \nRecommendations 1 .2.1 to 1.2.5 and 1 .2.8 \nWhy the c ommi ttee made the r ecommenda tions \nOverall, t here was limit ed new e vidence on t he accuracy of diff erent met hods of \nmeasuring blood pr essur e. Most of t he studies identified w ere small, and t he populations \nand pr otocols f or measur ement v aried making int erpretation difficult. Ho wever, the \ncommitt ee agr eed t hat it was impor tant t o focus on t he evidence fr om t hese mor e recent \nstudies (post -2000) because t he evidence should r eflect t he curr ent use of electr onic \nsphygmomanomet ers, which ha ve replaced mer cury-based sph ygmomanomet ers. \nThe e vidence did not sho w that changing t he curr ent blood pr essur e thresholds f or clinic \nmeasur ement or home blood pr essur e monit oring (HBPM) w ould impr ove diagnostic \naccuracy compar ed wit h ambulat ory blood pr essur e monit oring (ABPM), so t he committ ee \nagreed t he 2011 t hresholds f or diagnosis should be r etained. The committ ee not ed that \nthese ar e in line wit h most int ernational guidance. \nLimit ed evidence suggest ed that clinic blood pr essur e measur ement is less accurat e than \nHBPM or ABPM when used t o diagnose h yper tension. The committ ee members \nackno wledged t hat t hese findings w ere in line wit h their clinical e xperience and agr eed", "people wit h diabet es, pr egnant w omen, people wit h kidne y disease and people \ntaking some antih yper tensiv e drugs, such as A CE inhibit ors and angiot ensin  II \nrecept or block ers. Encourage salt r eduction in t hese gr oups. [2004 , amended \n2019] \n1.4.6 Do not off er calcium, magnesium or potassium supplement s as a met hod f or \nreducing blood pr essur e. [2004] \n1.4.7 Offer advice and help t o smok ers t o stop smoking. See NICE's guideline on \ntobacco . [2004] \n1.4.8 Inform people about local initiativ es by, for example, healt hcare teams or patient \norganisations t hat pr ovide suppor t and pr omot e healt hy lifestyle change, \nespecially t hose t hat include gr oup w ork f or motiv ating lif estyle change. [2004] \nFor a shor t explanation of wh y the committ ee delet ed the recommendation on \nrelaxation t herapies and ho w this might aff ect practice, see t he rationale and impact \nsection on r elaxation t herapies . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview H: \nrelaxation t herapies . \nStarting an tihyper tensi ve drug tr eatmen t \nNICE has pr oduced a patient decision aid on tr eatment options f or hyper tension  to help \npeople and t heir healt hcare professionals discuss t he diff erent types of tr eatment and Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 11 of\n52 make a decision t hat is right f or each person. \nFor advice on shar ed decision making f or medicines, see t he inf ormation on patient \ndecision aids in NICE's guideline on medicines optimisation . \nTo suppor t adher ence and ensur e that people wit h hyper tension mak e the most eff ectiv e \nuse of t heir medicines, see NICE's guideline on medicines adher ence . \n1.4.9 Offer antih yper tensiv e drug tr eatment in addition t o lifestyle advice t o adult s of"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "Feedback: The response provided is completely correct, accurate, and factual. It matches the reference answer by identifying the National Institute for Health and Care Excellence (NICE) as the organization that provides guidelines for hypertension diagnosis and management in adults. The response even goes further to give the full name of the organization, which aligns with the information required by the instruction."}, {"question": "Which group of people should not use salt substitutes containing potassium chloride?", "generated_answer": "Based on the context, the group of people who should not use salt substitutes containing potassium chloride is not explicitly mentioned. However, it is mentioned in section 1.4.50 that when using further diuretic therapy for step 4 treatment of resistant hypertension, monitoring blood sodium and potassium and renal function within 1 month of starting treatment and repeat as needed thereafter is recommended. \n\nIt is also mentioned in section 1.4.51 that considering an alpha-blocker or beta-blocker for adults with resistant hypertension starting step 4 treatment who have a blood potassium level of more than 4.5 mmol/l is recommended.\n\nTherefore, it can be inferred that individuals with a blood potassium level of more than 4.5 mmol/l should exercise caution when using salt substitutes containing potassium chloride, but it is not explicitly stated that they should not use them.", "true_answer": "Older people, people with diabetes, pregnant women, people with kidney disease, and people taking some antihypertensive drugs, such as ACE inhibitors and angiotensin II receptor blockers.", "relevant_docs": ["estimat ed glomerular filtration rat e because t hey have an incr eased risk of \nhyperkalaemia. [2019] \nIn Mar ch 2019 , this was an off -label use of some pr eparations of spir onolact one. \nSee NICE's inf ormation on pr escribing medicines . \n1.4.50 When using fur ther diur etic t herap y for st ep 4 treatment of r esistant \nhyper tension, monit or blood sodium and potassium and r enal function wit hin \n1 mont h of star ting tr eatment and r epeat as needed t hereafter. [2019] \n1.4.51 Consider an alpha-block er or beta-block er for adult s wit h resistant h yper tension \nstarting st ep 4 treatment who ha ve a blood potassium le vel of mor e than \n4.5 mmol/l. [2019] \n1.4.52 If blood pr essur e remains uncontr olled in people wit h resistant h yper tension \ntaking t he optimal t olerat ed doses of 4  drugs, seek specialist advice. [2019] \nFor a shor t explanation of wh y the committ ee made t he 2019 r ecommendations and \nhow they might aff ect practice, see t he rationale and impact section on st ep 4 \ntreatment . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview G: \nstep 4 treatment . Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 23 of\n52 1.5 Identifying w ho to r efer for same-da y spe cialist \nreview \n1.5.1 If a person has se vere hyper tension ( clinic blood pr essur e of 180/120  mmHg or \nhigher), but no sympt oms or signs indicating same-da y referral (see \nrecommendation 1 .5.2), carr y out in vestigations f or tar get or gan damage (see \nrecommendation  1.3.3) as soon as possible: \n\u2022 If tar get or gan damage is identified, consider star ting antih yper tensiv e drug \ntreatment immediat ely, without waiting f or the result s of ABPM or HBPM. \n\u2022 If no tar get or gan damage is identified, confirm diagnosis b y:", "consultation wit h them and t heir f amilies and car ers or guar dian. \nAll pr oblems (adv erse e vents) related to a medicine or medical de vice used f or treatment \nor in a pr ocedur e should be r epor ted to the Medicines and Healt hcare product s Regulat ory \nAgency using t he Yellow Car d Scheme . \nLocal commissioners and pr oviders of healt hcare have a responsibility t o enable t he \nguideline t o be applied when individual pr ofessionals and people using ser vices wish t o \nuse it. The y should do so in t he cont ext of local and national priorities f or funding and \ndeveloping ser vices, and in light of t heir duties t o have due r egar d to the need t o eliminat e \nunlawful discrimination, t o adv ance equality of oppor tunity and t o reduce healt h \ninequalities. Not hing in t his guideline should be int erpreted in a wa y that w ould be \ninconsist ent wit h complying wit h those duties. \nCommissioners and pr oviders ha ve a responsibility t o promot e an en vironmentally \nsustainable healt h and car e syst em and should assess and r educe t he en vironmental \nimpact of implementing NICE r ecommendations  wher ever possible. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 2 of\n64 Contents \nOverview ...................................................................................................................................... 5 \nWho is it f or? .......................................................................................................................................... 6 \nRecommendations ....................................................................................................................... 7 \n1.1 Initial clinical assessment ................................................................................................................ 9"], "eval_score_GPT4": "3", "eval_feedback_GPT4": "Feedback: The response provided does not directly answer the question regarding which specific groups of people should not use salt substitutes containing potassium chloride. Instead, it infers from medical guidelines that individuals with a blood potassium level of more than 4.5 mmol/l should be cautious. This is somewhat related to the question as it touches on the issue of high potassium levels, which is relevant to the use of potassium chloride. However, it fails to mention any specific groups such as older people, people with diabetes, pregnant women, people with kidney disease, and those taking certain antihypertensive drugs, which are all mentioned in the reference answer. Therefore, the response is somewhat correct but lacks the specificity and directness of the reference answer."}, {"question": "What is accelerated hypertension also known as?", "generated_answer": "According to the context, accelerated hypertension is also known as \"malignant hypertension\".", "true_answer": "Malignant hypertension.", "relevant_docs": ["nerve). It is usually associat ed wit h new or pr ogressiv e tar get or gan damage and is also \nknown as malignant h yper tension. \nEstab lishe d cardiovascular dise ase \nMedical hist ory of ischaemic hear t disease, cer ebrovascular disease, peripheral v ascular \ndisease, aor tic aneur ysm or hear t failure. Car diovascular disease is a general t erm f or \nconditions aff ecting t he hear t or blood v essels. It is usually associat ed wit h a build-up of \nfatty deposit s inside t he ar teries (at heroscler osis) and an incr eased risk of blood clot s. It \ncan also be associat ed wit h damage t o arteries in or gans such as t he brain, hear t, kidne ys \nand e yes through deposition of glassy mat erial wit hin the ar tery walls (ar terioscler osis). \nCardiovascular disease is 1 of t he main causes of deat h and disability in t he UK, but it can \noften lar gely be pr evented by leading a healt hy lifestyle. \nMasked hyper tension \nClinic blood pr essur e measur ement s are normal (less t han 140/90  mmHg), but blood \npressur e measur ement s are higher when tak en out side t he clinic using a verage da ytime \nambulat ory blood pr essur e monit oring (ABPM) or a verage home blood pr essur e monit oring \n(HBPM) blood pr essur e measur ement s. \nPersisten t hyper tension \nHigh blood pr essur e at r epeat ed clinical encount ers. \nStage 1 hyper tension \nClinic blood pr essur e ranging fr om 140/90  mmHg t o 159/99  mmHg and subsequent ABPM Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 25 of\n52 daytime a verage or HBPM a verage blood pr essur e ranging fr om 135/85  mmHg t o 149/\n94 mmHg. \nStage 2 hyper tension \nClinic blood pr essur e of 160/100  mmHg or higher but less t han 180/120  mmHg and \nsubsequent ABPM da ytime a verage or HBPM a verage blood pr essur e of 150/95  mmHg or \nhigher .", "estimat ed glomerular filtration rat e because t hey have an incr eased risk of \nhyperkalaemia. [2019] \nIn Mar ch 2019 , this was an off -label use of some pr eparations of spir onolact one. \nSee NICE's inf ormation on pr escribing medicines . \n1.4.50 When using fur ther diur etic t herap y for st ep 4 treatment of r esistant \nhyper tension, monit or blood sodium and potassium and r enal function wit hin \n1 mont h of star ting tr eatment and r epeat as needed t hereafter. [2019] \n1.4.51 Consider an alpha-block er or beta-block er for adult s wit h resistant h yper tension \nstarting st ep 4 treatment who ha ve a blood potassium le vel of mor e than \n4.5 mmol/l. [2019] \n1.4.52 If blood pr essur e remains uncontr olled in people wit h resistant h yper tension \ntaking t he optimal t olerat ed doses of 4  drugs, seek specialist advice. [2019] \nFor a shor t explanation of wh y the committ ee made t he 2019 r ecommendations and \nhow they might aff ect practice, see t he rationale and impact section on st ep 4 \ntreatment . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview G: \nstep 4 treatment . Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 23 of\n52 1.5 Identifying w ho to r efer for same-da y spe cialist \nreview \n1.5.1 If a person has se vere hyper tension ( clinic blood pr essur e of 180/120  mmHg or \nhigher), but no sympt oms or signs indicating same-da y referral (see \nrecommendation 1 .5.2), carr y out in vestigations f or tar get or gan damage (see \nrecommendation  1.3.3) as soon as possible: \n\u2022 If tar get or gan damage is identified, consider star ting antih yper tensiv e drug \ntreatment immediat ely, without waiting f or the result s of ABPM or HBPM. \n\u2022 If no tar get or gan damage is identified, confirm diagnosis b y:"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "Feedback: The response provided is completely correct, accurate, and factual. It matches the reference answer by stating that accelerated hypertension is also known as \"malignant hypertension,\" which is the expected response."}, {"question": "Are digital inhalers recommended for routine use in asthma management by the NHS?", "generated_answer": "No, digital inhalers are not recommended for routine use in asthma management by the NHS. The committee concluded that digital inhalers are not a cost-effective option for routine use in asthma.", "true_answer": "No, digital inhalers are not recommended for routine use in asthma management by the NHS.", "relevant_docs": ["terms of baseline adher ence and ast hma contr ol, and benefit was generally mor e likely in \nthe studies of people wit h poor er baseline v alues. \nDigital inhalers ar e mor e expensiv e than con ventional de vices, par tly because of t he \ndevice it self and par tly because of t he set -up and monit oring r equir ement s. The \ncommitt ee concluded t hat digital inhalers ar e not a cost -effectiv e option f or routine use in \nasthma. Ho wever, they are pot entially v aluable in select ed people wit h ast hma, f or \nexample t hose in whom t he need f or biologic t herap y is being consider ed and t here is a \nneed t o confirm good adher ence. Further r esear ch is needed t o identify mor e precisely t he \npeople and t he cir cumstances in which t hey might be used . \nHow the r ecommenda tion mig ht affect practice \nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \ncurrent practice. \nReturn t o recommendations \nMedicines f or the ini tial manag emen t of newly \ndiagnose d asthma in pe ople ag ed 12 and o ver \nRecommendations 1 .7.1 and 1 .7.2 \nWhy the c ommi ttee made the r ecommenda tions \nThe committ ee look ed at e vidence comparing 3 tr eatment options in people aged 12 and \nover wit h a new diagnosis of ast hma. These w ere SABA as needed wit h no ICS; r egular \nlow-dose ICS plus SABA as needed; and a combination inhaler of an ICS (budesonide) plus \nformot erol, a f ast onset long-acting beta 2 agonist (L ABA), used as needed (as-needed \nAIR). \nThe most impor tant diff erence betw een t he gr oups was a r eduction in se vere \nexacerbations of ast hma in t he gr oup using as-needed AIR t herap y, and t his applied t o the Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 51 of", "practice. \nWe have also made some minor changes \u2013 f or example f or clarity or wher e \nrecommendations ha ve been amalgamat ed. These r ecommendations ar e mark ed [NICE \n2017] , [NICE 2017 , amended NICE 2021] or [BTS/SIGN 2019] . \nMarch 2021: In recommendations 1 .14.1 and 1 .14.3, NICE clarified t hat appr oaches t o \nminimising indoor air pollution and r educing e xposur e to out door air pollution should be \nincluded in a personalised action plan because pollution can trigger and e xacerbat e \nasthma. \nFebruar y 2020:  NICE r eview ed the evidence on incr easing t he dose of inhaled \ncorticost eroids wit hin a self -management pr ogramme in childr en and y oung people wit h \nasthma and r emoved a r ecommendation. A new r ecommendation on self -management in \nchildr en and y oung people was made. This r ecommendation is mark ed [2020 , amended \nBTS/NICE/SIGN 202 4]. \nBTS ISBN: 9 78-1-917 619-01-1 \nNICE ISBN: 9 78-1-47 31-6612- 7 \nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 64 of\n64"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided aligns with the reference answer in stating that digital inhalers are not recommended for routine use in asthma management by the NHS. The additional detail about the committee's conclusion on cost-effectiveness is not present in the reference answer but does not contradict the main point of the reference answer. Therefore, the response is completely correct, accurate, and factual based on the reference answer."}, {"question": "What FeNO level indicates a diagnosis of asthma in children?", "generated_answer": "Unfortunately, the context provided does not specify a particular FeNO level that indicates a diagnosis of asthma in children. It only mentions that a raised measurement (suggesting asthma) should be regarded as one above the upper end of the local reference range for eosinophil counts and IgE levels.", "true_answer": "35 ppb or more.", "relevant_docs": ["asthma \n\u2022 evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \npeople suspect ed of ast hma \n\u2022 evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or \nthe diagnosis of ast hma \n\u2022 evidence r eview  D: accuracy of skin prick t est in childr en for the diagnosis of \nasthma \n\u2022 evidence r eview E: diagnostic t est accuracy of IgE in childr en \n\u2022 evidence r eview  F: diagnostic accuracy of fractional e xhaled nitric o xide (F eNO) \nmeasur es \n\u2022 evidence r eview  G: diagnostic accuracy of eosinophil blood count measur es in t he \ndiagnosis of ast hma \n\u2022 evidence r eview  H: br onchial challenge wit h histamine and met hacholine f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  I: bronchial challenge t est wit h mannit ol \n\u2022 evidence r eview  J: bronchial challenge t esting in r esponse t o exercise f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 13 of\n64 1.3 D iagnosing asthma in childr en under 5 \nDiagnosis is har d in t his age gr oup because it is difficult t o do t he tests and t here are no \ngood r eference standar ds. \n1.3.1 For childr en under 5 wit h suspect ed ast hma, tr eat wit h inhaled cor ticost eroids in \nline wit h the recommendations on medicines f or initial management in childr en \nunder  5, and r eview t he child on a r egular basis. If t hey still ha ve sympt oms when \nthey reach 5 y ears, att empt objectiv e tests (see t he section on objectiv e tests for \ndiagnosing ast hma in adult s, young people and childr en aged 5 t o 16). [NICE \n2017] \n1.3.2 If a child is unable t o per form objectiv e tests when t hey are aged 5:", "conditions#notice-of -right s).Page 42 of\n64 similar inf ormation t o a pr eceding one. Practical aspect s were tak en int o account using t he \ncommitt ee's kno wledge and e xperience. These included t he availability of t he tests, which \nvaries considerably (in par ticular , bronchial challenge t esting is not a vailable in primar y \ncare and not r eadily a vailable in secondar y car e), the ability of people t o per form t he tests, \nand t he acceptability of t he tests to the person, which is par ticularly r elevant in y ounger \nchildr en. \nThe committ ee also consider ed the cost of t he available t ests. Ho wever, no healt h \neconomic study on t he most cost -effectiv e sequence or combination of t ests was \nidentified. Ther efore, a healt h economic model was de veloped t o help addr ess t his. \nThe committ ee discussed what cut -off v alues should be r ecommended f or the tests. For \nsome of t he tests it was agr eed t hat it was inappr opriat e to stat e a numerical v alue f or an \nabnormal r esult. F or example, normal ranges f or blood t ests ma y vary slight ly betw een \nlaborat ories. Ther efore, for eosinophil count s and IgE le vels, a raised measur ement \n(suggesting ast hma) should be r egar ded as one abo ve the upper end of t he local \nreference range. Ther e are also se veral standar dised met hods of per forming br onchial \nchallenge t ests, and t he definition of br onchial h yperr esponsiv eness will be dependent on \nthe met hod used. \nSpirometr y should alwa ys be per formed using an int ernational standar d protocol but t he \nmethod of e xpressing r eversibility aft er br onchodilat or varies. Ideally t his w ould be based \non change in z-scor es, but t hese ar e not measur ed by all spir ometr y equipment. Change in \nabsolut e values of FEV 1 is arguably best giv en as t he per centage change compar ed wit h \nthe person's pr edict ed FEV 1, and using t his paramet er a change of 10% or mor e is"], "eval_score_GPT4": "1", "eval_feedback_GPT4": "Feedback: The response does not provide a specific FeNO level, which is required to answer the question accurately. Instead, it discusses the general concept of a raised measurement without giving the exact value. According to the reference answer, the specific FeNO level that indicates a diagnosis of asthma in children is 35 ppb or more. Since the response fails to mention this specific value, it does not meet the criteria for being correct, accurate, and factual."}, {"question": "How many asthma deaths were there in the UK in 2018?", "generated_answer": "According to the context, there were more than 1,400 asthma deaths in the UK in 2018, an increase of 8% compared to 2017.", "true_answer": "More than 1,400 asthma deaths.", "relevant_docs": ["(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 61 of\n64 Context \nThe NICE guideline on ast hma was published in 2017 and BTS/SIGN last updat ed their \nasthma guideline  in 2019 . The guidelines o verlap in t he clinical ar eas included, and \nhealt hcare practitioners in t he UK ha ve been using bot h set s of guidance. \nHowever, these guidelines diff er in t heir appr oach t o diagnosis. Concern has been raised \nabout t he recommendations t o use fractional e xhaled nitric o xide (F eNO) measur ement \nand spir ometr y mor e widely , contained in NICE guidance. Lik ewise, t here are significant \ndifferences in se veral aspect s of t he tr eatment appr oach in each. BTS, NICE and SIGN \nagreed t hat updating and unifying curr ent guidance w ould be helpful f or healt hcare \nprofessionals. \nThis updat e to national ast hma guidelines is timely f or people wit h ast hma and t heir \nhealt hcare teams. Ther e have been v arious initiativ es that aim t o impr ove out comes f or \npeople wit h ast hma in t he UK, but out comes ne vertheless r emain poor . Mor tality fr om \nasthma continues t o incr ease in t he UK, and it r emains a leading cause of morbidity . \nAccor ding t o the Office f or National Statistics, t here were mor e than 1 ,400 ast hma deat hs \nin the UK in 2018 , an incr ease of 8% compar ed wit h 2017 . For out comes t o impr ove, people \nwith ast hma need e xcellent, e vidence-based car e. \nTher e are man y uncer tainties about t he best wa y to diagnose, monit or and tr eat ast hma. \nFor example, t here have been r ecent de velopment s in our understanding of t he value of \nphysiological t ests. Also, t here are new options f or the use of inhaled cor ticost eroids and \nwhat t o do when tr eatment needs t o be st epped up or do wn. The e vidence in t hese ar eas", "on: \n\uff0d vulnerable gr oups in t he NICE guideline on air pollution: out door air \nquality and healt h Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 29 of\n64 \uff0d people wit h ast hma, ot her r espirat ory conditions or car diovascular \nconditions in t he NICE guideline on indoor air quality at home , and \n\u2022 smoking in t he NICE guideline on t obacco . [NICE 2017 , amended 2021; BTS/\nSIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.14.2 Review t he cont ent of t he personalised action plan, and check t hat t he person \nunderstands it, at t he following: \n\u2022 hospital admission, including in vir tual war ds \n\u2022 acute consultations in primar y car e or emer gency depar tment \n\u2022 annual r eviews. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.14.3 Consider an ast hma self -management pr ogramme, comprising a writt en \npersonalised action plan (including appr oaches t o minimising e xposur e to indoor \nand out door air pollution) and education, f or the families or car ers of childr en \nunder 5 wit h suspect ed or confirmed ast hma. [NICE 2017 , amended NICE 2021] \n1.14.4 For adult s (aged 17 and o ver) who ar e using an inhaled cor ticost eroid (ICS) in a \nsingle inhaler , offer an incr eased dose of ICS f or 7 da ys, wit hin a self -\nmanagement pr ogramme, when ast hma contr ol det eriorat es. Clearly out line in t he \nperson's ast hma action plan ho w and when t o do t his, and what t o do if \nsympt oms do not impr ove. \nWhen incr easing ICS tr eatment: \n\u2022 consider quadrupling t he regular ICS dose \n\u2022 do not e xceed t he maximum licensed daily dose. [NICE 2017] \n1.14.5 Include advice in self -management pr ogrammes on contacting a healt hcare \nprofessional f or a r eview if ast hma contr ol det eriorat es (see t he \nrecommendations on monit oring ast hma contr ol). [NICE 2020 , amended BTS/"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided matches the reference answer by stating that there were more than 1,400 asthma deaths in the UK in 2018. This information is correct and factual, aligning with the reference answer. Additionally, the response includes an extra piece of information regarding the percentage increase compared to the previous year, which is not required by the instruction but does not detract from the accuracy of the response concerning the number of asthma deaths."}, {"question": "What level of FeNO is considered reasonably specific for asthma in children with a suggestive history?", "generated_answer": "According to the context, a cut-off value of 35 ppb is agreed upon for children, indicating that this level of FeNO is considered reasonably specific for asthma in children with a suggestive history.", "true_answer": "35 ppb or more.", "relevant_docs": ["the person's pr edict ed FEV 1, and using t his paramet er a change of 10% or mor e is \nabnormal. Using t he mor e traditional means of e xpressing t he change as a per centage of \nthe baseline FEV 1, increased r eversibility w ould be 12% or mor e in adult s and childr en. In \nadult s, the change should also be 200 ml or mor e. The committ ee agr eed t o include bot h \nways of measuring r eversibility in it s recommendations. \nAn optimal cut -off v alue is also difficult t o giv e for FeNO (fractional e xhaled nitric o xide). \nTher e is good e vidence t hat F eNO le vels incr ease wit h age and wit h height, and ideally \nnormal ranges w ould be a vailable which corr ect f or these f actors. Ho wever, there are \ncurrently no standar d char ts and F eNO equipment does not giv e an age/height corr ected \noutput. Alt hough not ideal, t he committ ee agr eed t hat t hey need t o suggest a simple cut -\noff v alue. And because F eNO is t he first, and possibly t he only , test in t he recommended \nsequences in bot h adult s and childr en they agr eed t hat t he value should be r easonably \nhigh so t hat it w ould be specific, ackno wledging t hat t his sacrifices a degr ee of sensitivity . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 43 of\n64 Cut-offs of 50 ppb in adult s and 35 ppb in childr en w ere agr eed. \nNo e vidence was a vailable f or diagnostic t ests in childr en under 5 . The age at which a \nchild can co-operat e wit h tests will v ary, but t he committ ee agr eed t hat it is usually \nnecessar y to manage t hese childr en pragmatically based on sympt oms and signs only . \nAdult s \nSeveral t ests sho wed good specificity f or ast hma, wit h values o ver 80% f or blood \neosinophils, F eNO ( cut-off v alues 40-50 ppb ), peak e xpirat ory flow (PEF) v ariability ,", "asthma, or wit h ast hma sympt oms t hat ar e uncontr olled on t heir curr ent tr eatment. \nSee also algorit hm E f or a summar y of t he pharmacological management of ast hma in \nchildr en under 5 . \n1.9.1 Consider an 8 t o12 w eek trial of twice-daily paediatric lo w-dose inhaled \ncorticost eroid (ICS) as maint enance t herap y (wit h a shor t-acting beta 2 agonist \n[SABA] f or reliever therap y) in childr en under  5 wit h suspect ed ast hma and: \n\u2022 sympt oms at pr esentation t hat indicat e the need f or maint enance t herap y \n(for example, int erval sympt oms in childr en wit h anot her atopic disor der), or \n\u2022 severe acut e episodes of difficulty br eathing and wheez e (for example, \nrequiring hospital admission, or needing 2 or mor e courses of oral \ncorticost eroids). [BTS/NICE/SIGN 202 4] \n1.9.2 If sympt oms do not r esolv e during t he trial period, tak e the following sequential \nsteps: \n\u2022 check inhaler t echnique and adher ence \n\u2022 check whet her t here is an en vironmental sour ce of t heir sympt oms (f or \nexample mould in t he home, cold housing, smok ers or indoor air pollution) \n\u2022 review whet her an alt ernativ e diagnosis is lik ely. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 25 of\n64 If none of t hese e xplain t he failure to respond t o treatment, r efer the child t o \na specialist in ast hma car e. [BTS/NICE/SIGN 202 4] \n1.9.3 Consider st opping ICS and SABA tr eatment aft er 8 t o 12 weeks if sympt oms ar e \nresolv ed. R eview t he sympt oms aft er a fur ther 3 mont hs. [BTS/NICE/SIGN 202 4] \n1.9.4 If sympt oms r esolv e during t he trial period, but t hen: \n\u2022 sympt oms r ecur b y the 3-mont h review , or \n\u2022 the child has an acut e episode r equiring syst emic cor ticost eroids or"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided correctly identifies the FeNO level of 35 ppb as being reasonably specific for asthma in children with a suggestive history. This matches the reference answer, which also states \"35 ppb or more.\" Therefore, the response is completely correct, accurate, and factual."}]